Funding and Survival Comparisons with other cancers:
The graph below shows the trend in survival since 1971 to 2009 for major tumour sites, including pancreatic cancer. It is clear that in some cases vast improvement in survival has been achieved for these tumour sites. The notable exception is pancreatic cancer where change has amounted to a fraction of a per cent.
Pancreatic cancer receives only one per cent of research funding:
While funding for pancreatic cancer research has increased marginally over the past 10 years it still accounts for only one per cent of overall research funding and only two per cent of site-specific funding. This is despite it being the fifth largest cause of cancer death in the UK.
Of the £521 million spent by the National Cancer Research Institute partners (NCRI) in 2011, only £5 million was spent on pancreatic cancer. In contrast, Breast cancer received £42 million, Bowel cancer, £23million, Leukaemia £32 million, and Prostate £17million.
Ovarian cancer, which affects 6,955 women annually,(approx. 1400 fewer than pancreatic cancer) received nearly three times more funding than pancreatic cancer in 2011. Ovarian cancer has a 41 per cent five-year survival rate, pancreatic cancer has just over a three per cent survival rate.
The table below highlights some of the funding inequalities that exist by cancer site. With a comparison of survival rates from the 1970s and current, along with incidence and mortality data, it is clear to see a correlation between investment in research funding and improvement in survival rates. Lack of investment in pancreatic cancer research is illustrated by the fact that survival rates for the disease have not changed over this period.
The following graph looks at the actual annual spend by the National Cancer Research Institute Partners per cancer site between 2002 and 2007 and the age-standardised* mortality rates per annum per cancer site during the same period:
Comparing the NCRI Partners spend on specific cancers related to the percentage of total cancer deaths in the UK by tumour site:
Cancer Research UK (CRUK) is one of the major investors in pancreatic cancer research in the UK. However, pancreatic cancer is still the poor relation in terms of CRUK research funding in comparison with other cancers:
The information provided in this site, or through links to other websites, is not a substitute for medical or professional care and should not be relied upon as such. Read our disclaimer.